This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The effectiveness evidence was derived from five primary studies.
Methods of combining primary studies
The primary studies were combined using narrative methods.
Investigation of differences between primary studies
Results of the review
In the individual-based model, the transmission rates were 0.10 for ECS and 0.19 for vaginal delivery when no ART was used, 0.034 (ECS) and 0.071 (vaginal) when ZDV prophylaxis was used, and 0.01 (ECS) and 0.03 (vaginal) when combination ART was used.
In the population-based model, 4,958 HIV-infected women delivered annually, 68% of the women received ART during pregnancy, and the HIV seroprevalence among pregnant women in the USA was 1.7 per 1,000 pregnant women.
Methods used to derive estimates of effectiveness
The authors made several assumptions to support the lack of, or variability of, published data used in the decision models.
Estimates of effectiveness and key assumptions
The following assumptions were made: each woman received HIV counselling and testing according to current US Public Health Service recommendations; all women not receiving ECS delivered vaginally;
HIV-infected women refrained from breast-feeding; all children received formula;
ART had no subsequent impact on maternal health; and ZDV was administered according to US Public Health Service recommendations.
In the population-based analysis, it was assumed that among women receiving ART, 29% received ZDV prophylaxis and the remaining 71% received combination ART. It was also assumed that 6% of the women receiving combination ART discontinued the therapy due to adverse events.
Measure of benefits used in the economic analysis
Two benefit measures were used in the economic analysis. One was the number of cases of mother-to-child transmission of HIV avoided, which was derived from the decision model only. The other was the child life-years saved, which was calculated also on the basis of the difference between the average US life expectancy of 75.8 years and the estimated life expectancy of 9.4 years for a HIV-infected child.
Direct costs
Discounting was carried out at a rate of 5%. The unit costs and the quantities of resources were not reported separately. The cost/resource boundary adopted in the analysis was that of the health care system. The costs of ART, mode of delivery (ECS or vaginal delivery), with or without morbidity, and paediatric care were estimated. Single cost items included in the analysis were not reported. The costs and the quantities were estimated from published data. The total costs of each intervention were calculated by modelling. All of the costs were inflated to 1998, which represented the price year.
Statistical analysis of costs
Statistical analyses of the costs were not carried out.
Indirect Costs
The indirect costs were not included.
Currency

US dollars ($).
Sensitivity analysis
Sensitivity analyses were carried out to assess the impact of some model parameters on the estimated cost-effectiveness ratios. The parameters varied were: the vertical transmission rates, according to maternal HIV disease status and to mode of delivery; the discounted lifetime treatment cost of paediatric HIV disease; and the postpartum morbidity rates in the individual-based model, and the maternal HIV prevalence rates and the percentage of women receiving ART in the population-based model.
